Curcuma longa L. (Zingiberaceae): technological development for application as an auxiliary therapeutic agent in the treatment of patients with Alzheimer's Disease

Ayla Winnie Ramos da Silva
Renata Biegelmeyer

    Ayla Winnie Ramos da Silva

    1Federal University of Bahia, Faculty of Pharmacy, Rua Barão do Jeremoabo, 147, Ondina, CEP 40170-115, Salvador, BA, Brazil.

    I have a degree in Pharmacy from the Federal University of Bahia. I monitored the following curricular components: Metabolic Biochemistry for Pharmacy (05/2015 to 11/2015) and Physical Methods of Applied Analysis (11/2017 to 02/2018); volunteer intern at the clinical biochemistry laboratory (01/2016 to 07/2016). I presented my Course Conclusion Paper (06/2019) with a theme in the areas of pharmacognosy and pharmacology.

    Renata Biegelmeyer

    Federal University of Bahia, Faculty of Pharmacy, Rua Barão de Jeremoabo 147, Ondina, CEP 40170-115, Salvador, BA, Brazil.

    Graduated in Pharmacy with an emphasis on Industrial Pharmacy from the Federal University of Rio Grande do Sul (2009) and PhD in Pharmaceutical Sciences from the same University (2013). He completed a Sandwich Doctorate Abroad (CAPES-PDSE) at the University of California, San Diego in 2012; acting in the areas of isolation of metabolites from marine sponges, semisynthesis of natural products and structural clarification. Worked with the Ministry of Health as a collaborator in the project: "Oriented studies for the review, analysis and systematization of scientific information for the species listed in RENISUS". He held a post-doctorate at UFRGS in the area of ​​Pharmaceutical Technology and Natural Products (2014-2017). In 2016, she was a substitute professor at the Federal University of Health Sciences of Porto Alegre (UFCSPA). Worked as a collaborator of the Brazilian Pharmacopeia, in the preparation of monographs of medicinal plants. She is currently an adjunct professor in the Department of Medicines at the Faculty of Pharmacy of the Federal University of Bahia (UFBA). Has experience in Pharmacy, with emphasis on Pharmacognosy, Chemistry of Natural Products, Biological Tests, Quality Control, Pharmaceutical Technology and Cosmetology.

Keywords

Alzheimer's
Turmeric
Treatment
Curcumin
Neurodegenerative
Bioavailability

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder that causes brain atrophy, leading to dementia in elderly. Considering that there is no known cure, the available drug treatments are related to alleviate the symptoms. Among the alternative treatments, Curcuma longa L. showed anti-inflammatory and antioxidant properties, important for the process of AD progression. Despite its benefits, it has been shown low bioavailability in studies performed. In the present review, we aimed to search the literature for alternatives to improve the bioavailability of C. longa for application in the treatment of Alzheimer's disease. Thus, a bibliographic review was performed in scientific databases, using a clear and inclusive search strategy. 93 articles were found and 32 were selected. Among the alternatives, pharmaceutical formulations showed featured, such as nanoparticles, micelles and emulsions. The pharmacological properties of C. longa and the many possibilities of altering its bioavailability, justify the importance to development of studies directed to use these compounds in AD therapy. Therefore, we hoped that these results may encourage further researches towards the development of C. longa-based phytotherapic and/or phytomedicines for the auxiliary treatment of Alzheimer's disease.

References

  1. Chang C-H, Lane H-Y, Lin C-H. Brain Stimulation in Alzheimer’s Disease. Front Psychiatry. 2018; 9(201): 1-13. ISSN 1664-0640. [CrossRef] [PubMed].
  2. Medlineplus: National Library of Medicine (EUA). Alzheimer’s disease [revisado em 17 de agosto de 2016]. Disponível em: [Link]. Acesso em: 08 nov. 2019.
  3. Cavalcanti JLS, Engelhardt E. Aspectos da fisiopatologia da doença de Alzheimer esporádica. Rev Bras Neurol. 2012; 48(4): 21-9. ISSN 2447-2573. Disponível em: [Link]. Acesso em: 10 nov. 2019.
  4. Magalingam KB, Radhakrishnan A, Ping,NS, Haleagrahara N. Current Concepts of Neurodegenerative Mechanisms in Alzheimer’s Disease. Biomed Res Int. 2018; 2018: 1-12. ISSN 2314-6141. [CrossRef] [PubMed].
  5. Forlenza OV. Tratamento farmacológico da doença de Alzheimer. Rev Psiquitr Clin. 2005; 32(3): 137-48. ISSN 0101-6083. [CrossRef].
  6. Smith MAC. Doença de Alzheimer. Rev Bras Psiquiatr. São Paulo, 1999; 21(2). ISSN 1809-452X. [CrossRef].
  7. Brasil. Ministério da Saúde. Protocolo Clínico e Diretrizes Terapêuticas – Doença de Alzheimer. Brasília, 2017. Disponível em: [Link]. Acesso em: 18 nov. 2019.
  8. Weller J, Budson A. Current understanding of Alzheimer’s disease diagnosis and treatment. F1000Res. 2018; 7: 1-9. ISSN 2046-1402. [CrossRef] [PubMed].
  9. Bui TT, Nguyen TH. Natural product for the treatment of Alzheimer’s disease. J Basic Clin Physiol Pharmacol. 2017; 28(5): 413-23. ISSN 0792-6855. [CrossRef] [PubMed].
  10. Trevisan MTS, Macedo FVV. Seleção de plantas com atividade anticolinesterase para tratamento da Doença de Alzheimer. Quim Nova. 2003; 26(3): 301-4. ISSN 1678-7064. [CrossRef].
  11. Martins DW, Lin HT, Paula CS. Extratos obtidos de plantas como fonte potencial para o tratamento da Doença de Alzheimer. Visão Acadêmica. Curitiba, 2016; 17(2): 16-39. ISSN 1518-8361. [CrossRef].
  12. Scholze AFA. Biodisponibilidade da curcumina. Rev Bras Nutrição Clin Func. 2014; 14(60): 20-24. ISSN 21764522. Disponível em: [Link]. Acesso em: 20/11/2019.
  13. Marchi JP et al. Curcuma longa L., o açafrão da terra, e seus benefícios medicinais. Arq Ciên Saúde UNIPAR. Umuarama, 2016; 20(3): 189-94. ISSN 1982-114X. [CrossRef].
  14. Sueth-Santiago V, Mendes-Silva GP, Decoté-Ricardo D, Lima MEF. Curcumina, o pó dourado do açafrão-da-terra: introspecções sobre química e atividades biológicas. Quim Nova. 2015; 38(4): 538-52. ISSN 1678-7064. [CrossRef].
  15. Del Prado-Audelo ML. Formulations of curcumin nanoparticles for brain diseases. Biomolecules. 2019; 9(2): 1-28. ISSN 2218-273X. [CrossRef] [PubMed].
  16. Sun M. et al. Advances in nanotechnology-based delivery systems for curcumin. Nanomedicine. 2012; 7(7): 1085-100. ISSN 1748-6963. [CrossRef] [PubMed].
  17. Jadhav NR, Nadaf SJ, Lohar DA, Ghagare PS, Powar TA. Phytochemicals formulated as nanoparticles: inventions, recent patents and future perspectives. Recent Pat Drug Delivery Formulation. 2017; 11(3): 173-86. ISSN 2212-4039. [CrossRef] [PubMed].
  18. Chin D, Huebbe P, Pallauf K, Rimbach G. Neuroprotective Properties of Curcumin in Alzheimer’s Disease - Merits and Limitations. Curr Med Chem. 2013; 20(32): 3955-85. ISSN 1875-533X. [CrossRef] [PubMed].
  19. Venigalla M, Sonego S, Gyengesi E, Sharman MJ, Münch G. Novel promising therapeutics against chronic neuroinflammation and neurodegeneration in Alzheimer’s disease. Neurochem Int. 2016; 95: 63-74. ISSN 0197-0186. [CrossRef] [PubMed].
  20. Marczylo TH, Verschoyle RD, Cooke DN, Morazzoni P, Steward WP, Gescher AJ. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemoth Pharm. 2007; 60(2): 171-7. ISSN 1432-0843. [CrossRef] [PubMed].
  21. Nahar P, Slitt AL, Seeram NP. Anti-Inflammatory Effects of Novel Standardized Solid Lipid Curcumin Formulations. J Med Food. 2015; 18(7): 1-7. ISSN 1557-7600. [CrossRef] [PubMed].
  22. Hagl S, Kocher A, Schiborr C, Kolesova N3, Frank J2, Eckert GP3. Curcumin micelles improve mitochondrial function in neuronal PC12 cells and brains of NMRI mice - impact on bioavailability. Neurochem Int. 2015; 89: 234-42. ISSN 0197-0186. [CrossRef] [PubMed].
  23. Koynova R, Tenchov B. Natural Product Formulations for the Prevention and Treatment of Alzheimer’s disease: A Patent Review. Recent Pat Drug Delivery Formulation. 2018; 12(1): 23-39. ISSN 2212-4039. [CrossRef] [PubMed].
  24. Massimino LC, Faria HAM, Yoshioka SA. Curcumin bioactive nanosizing: Increase of bioavailability. Ind Crop Prod. 2017; 109: 493-7. ISSN 0926-6690. [CrossRef].
  25. Kreuter J. Nanoparticle based drug delivery systems. J Control Rel. 1991; 16: 169-17. ISSN 1873-4995. [CrossRef].
  26. Mulik R, Mahadik K, Paradkar A. Development of curcuminoids loaded poly(butyl) cyanoacrylate nanoparticles: Physicochemical characterization and stability study. Eur J Pharm Sci. 2009; 37: 3-4, 395-404. ISSN 1879-0720. [CrossRef] [PubMed].
  27. Mhillaj E, Tarozzi A, Pruccoli L, Cuomo V, Trabace L, Mancuso C. Curcumin and heme oxygenase: Neuroprotection and beyond. Int J Mol Sci. 2019; 20(10). ISSN 1422-0067. [CrossRef] [ PubMed].
  28. Zou L, Liu W, Liu C, Xiao H, Mcclements DJ. Utilizing food matrix effects to enhance nutraceutical bioavailability: increase of curcumin bioaccessibility using excipient emulsions. J Agric Food Chem. 2015; 63(7), 2052-62. ISSN 1520-5118. [CrossRef] [ PubMed].
  29. Mcclements DJ, Xiao H. Excipient foods: designing food matrices that improve the oral bioavailability of pharmaceuticals and nutraceuticals. Food & Funct. 2014; 5(7): 1320-33. ISSN 2042-6496. [CrossRef] [ PubMed].
  30. Mcclure R, Ong H, Janve V, Barton S, Zhu M, Li B. Aerosol delivery of curcumin reduced amyloid-β deposition and improved cognitive performance in a transgenic model of Alzheimer's disease. Retriev J Alzheimers Dis. 2017; 55(2): 797-811. ISSN 1875-8908. [CrossRef] [PubMed].
  31. Schaffer M, Schaffer PM, Bar-Sela G. An update on Curcuma as a functional food in the control of cancer and inflammation. Curr Opin Clin Nutr Metab Care. 2015; 18(6): 605-11. ISSN 1363-1950. [CrossRef] [PubMed].
  32. Ghosh S, Banerjee S, Sil PC. The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: A recent update. Food Chem Toxicol. 2015; 83: 111-24. ISSN 0278-6915. [CrossRef] [PubMed].
  33. Jadhav N, Powar T, Shinde S, Nadaf S. Herbal nanoparticles: A patent review. Asian J Pharm. 2014; 8(1): 58-69. ISSN 1998-409X. [CrossRef].
  34. Wu B, Kulkarni K, Basu S, Zhang S, Hu M. First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics. J Pharm Sci. 2011; 100(9): 3655-81. ISSN 0022-3549. [CrossRef] [PubMed].
  35. Aggarwal BB, Harikumar KB. Potential Therapeutic Effects of Curcumin, the Anti-inflammatory Agent, Against Neurodegenerative, Cardiovascular, Pulmonary, Metabolic, Autoimmune and Neoplastic Diseases. The Int J Biochem Cell Biol. 2009; 41(1): 40-59. ISSN 1878-5875. [CrossRef] [PubMed].
  36. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998; 64(4): 353-6. ISSN 0032-0943. [CrossRef] [PubMed].
  37. Bairwa K, Grover J, Kania M, Jachak SM. ChemInform Abstract: Recent developments in chemistry and biology of curcumin analogues. RSC Advances. 2014; 45(34): 13946-78. ISSN 2046-2069. [CrossRef].
  38. Chang D et al. Herbal Medicine for the Treatment of Vascular Dementia: An Overview of Scientific Evidence. Evid Based Complement Altern Med. 2016; 2016(7293626): 1-15. ISSN 1741-4288. [CrossRef] [PubMed].
  39. D’Onofrio G et al. Phytochemicals in the Treatment of Alzheimer’s Disease: A Systematic Review. Curr Drug Targets. 2017; 18(13): 1487-98. ISSN 1389-4501. [CrossRef] [PubMed].
  40. Disilvestro RA, Joseph E, Zhao S, Bomser J. Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people. Nutr J. 2012; 11(79): 1-8. ISSN 1475-2891. [CrossRef] [PubMed].
  41. Baum L et al. Six-Month Randomized, Placebo-Controlled, Double-Blind, Pilot Clinical Trial of Curcumin in Patients With Alzheimer Disease. J Clin Psychopharm. 2008; 28(1): 110-3. ISSN 1533-712X. [CrossRef] [PubMed].
  42. Rainey-Smith SR et al. Curcumin and cognition: a randomised, placebo-controlled, double-blind study of community-dwelling older adults. Br J Nutr. 2016; 115(12): 2106-13. ISSN 1475-2662. [CrossRef] [PubMed].
  43. Guerreiro M. Testes de rastreio de defeito cognitivo e demência: uma perspectiva prática. Rev Port Med Geral Farm. 2010; 26(1): 46-53. ISSN 2182-5173. [CrossRef]
PDF (Portuguese)
HTML (Portuguese)
Save bookmark

Author(s)

  • Ayla Winnie Ramos da Silva
    1Federal University of Bahia, Faculty of Pharmacy, Rua Barão do Jeremoabo, 147, Ondina, CEP 40170-115, Salvador, BA, Brazil.
  • Renata Biegelmeyer
    Federal University of Bahia, Faculty of Pharmacy, Rua Barão de Jeremoabo 147, Ondina, CEP 40170-115, Salvador, BA, Brazil.

Metrics

  • Article viewed 1556 time(s)

How to Cite

1.
Curcuma longa L. (Zingiberaceae): technological development for application as an auxiliary therapeutic agent in the treatment of patients with Alzheimer’s Disease. Rev Fitos [Internet]. 2020 Aug. 20 [cited 2024 Nov. 19];14(2):249-58. Available from: https://revistafitos.far.fiocruz.br/index.php/revista-fitos/article/view/909
Crossref
Scopus
Google Scholar
Europe PMC
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2020 Revista Fitos

Report an error